RCUS Logo

Arcus Biosciences, Inc. (RCUS) 

NYSE
Market Cap
$1.41B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
1 of 971
Rank in Industry
1 of 557

Largest Insider Buys in Sector

RCUS Stock Price History Chart

RCUS Stock Performance

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Insider Activity of Arcus Biosciences, Inc.

Over the last 12 months, insiders at Arcus Biosciences, Inc. have bought $320M and sold $2.75M worth of Arcus Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Arcus Biosciences, Inc. have bought $140.4M and sold $2.99M worth of stock each year.

Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $1.6B.

The last purchase of 15,238,095 shares for transaction amount of $320M was made by GILEAD SCIENCES, INC. (10 percent owner) on 2024‑01‑29.

List of Insider Buy and Sell Transactions, Arcus Biosciences, Inc.

2024-08-13SaleChief Accounting Officer
1,357
0.0015%
$14.97$20,3140.00%
2024-03-27SaleChief Operating Officer
11,551
0.0123%
$17.55$202,720-11.31%
2024-03-18SaleChief Operating Officer
13,449
0.0154%
$17.92$240,941-5.57%
2024-02-27SalePresident
23,132
0.0255%
$20.10$464,953-18.68%
2024-02-27SaleChief Operating Officer
34,070
0.0376%
$20.11$685,148-18.68%
2024-02-26SalePresident
3,900
0.0044%
$20.06$78,234-16.48%
2024-02-26SaleChief Operating Officer
24,555
0.0276%
$20.07$492,819-16.48%
2024-01-29Purchase10 percent owner
15.24M
28.0689%
$21.00$320M+7.64%
2024-01-02SalePresident
6,975
0.0096%
$20.09$140,128-16.06%
2024-01-02SaleChief Financial Officer
2,004
0.0027%
$20.00$40,080-16.06%
2023-12-22SaleChief Operating Officer
21,521
0.028%
$17.76$382,213-9.97%
2023-12-01SaleChief Accounting Officer
282
0.0004%
$14.95$4,216+2.69%
2023-09-22SaleChief Operating Officer
21,369
0.0291%
$19.99$427,166-17.33%
2023-07-28SaleChief Operating Officer
45,000
0.0639%
$20.25$911,250-16.91%
2023-07-03SaleChief Accounting Officer
1,018
0.0014%
$20.41$20,777-17.18%
2023-06-28Purchase10 percent owner
1.01M
1.3257%
$19.26$19.45M-15.57%
2023-06-22SaleChief Operating Officer
12,437
0.0169%
$19.12$237,795-11.36%
2023-06-16SaleChief Operating Officer
12,563
0.017%
$19.35$243,094-11.87%
2023-06-07SaleChief Financial Officer
4,049
0.0054%
$20.04$81,142-15.94%
2023-03-16SaleChief Operating Officer
8,729
0.0119%
$16.81$146,734+7.46%

Insider Historical Profitability

4.73%
GILEAD SCIENCES, INC.10 percent owner
30061124
32.8495%
$15.4430<0.0001%
Jaen Juan C.President
1188233
1.2985%
$15.4489<0.0001%
Jarrett JenniferChief Operating Officer
215253
0.2352%
$15.44024
Goeltz II Robert C.Chief Financial Officer
51831
0.0566%
$15.4415+33.11%
Azoy AlexanderChief Accounting Officer
19070
0.0208%
$15.4403
ROSEN TERRY JChief Executive Officer
242173
0.2646%
$15.44216<0.0001%
FALBERG KATHRYN Edirector
102106
0.1116%
$15.4470+8.71%
Tang Carolyn C.General Counsel
28584
0.0312%
$15.4406
Grossman WilliamChief Medical Officer
20723
0.0226%
$15.4435+93.38%
KANEKO YASUNORIdirector
7133
0.0078%
$15.4410<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$186.92M10.899.9M-1.34%-$2.55M<0.01
State Street$92.6M5.394.9M+15.68%+$12.55M<0.01
The Vanguard Group$90.46M5.274.79M+2.36%+$2.09M<0.01
Fidelity Investments$90.23M5.264.78M+1.07%+$953,194.560.01
Woodline Partners LP$54.44M3.172.88M+178%+$34.86M0.47
Point72 Asset Management$36.15M2.111.91M+149.1%+$21.64M0.05
Dimensional Fund Advisors$30.61M1.781.62M+1.68%+$505,984.000.01
Invus Financial Advisors Llc$30.44M1.771.61M0%+$024.2
Boxer Capital, LLC$30.25M1.761.6M0%+$00.62
Ameriprise Financial$22.68M1.321.2M-26.53%-$8.19M0.01
Geode Capital Management$22.13M1.291.17M+2.61%+$562,693.10<0.01
AllianceBernstein$21.73M1.271.15M-2.94%-$657,326.090.01
Suvretta Capital Management, LLC$18.07M1.05957,3040%+$00.76
Morgan Stanley$16.52M0.96874,882+24.73%+$3.28M<0.01
Laurion Capital Management LP$10.34M0.6547,474New+$10.34M0.07
Northern Trust$9.69M0.57513,498-2.13%-$211,286.10<0.01
Charles Schwab$9.31M0.54493,276+4.47%+$398,254.72<0.01
BNY Mellon$7.56M0.44400,169-4.21%-$332,004.81<0.01
Panagora$7.37M0.43390,299+70.44%+$3.05M0.04
Macquarie Group$7.16M0.42379,1000%+$00.01
Ubs Asset Management Americas Inc$7.14M0.42378,063-5.17%-$388,984.62<0.01
Citadel Advisors LLC$6.7M0.39354,921+28.63%+$1.49M<0.01
Rafferty Asset Management Llc$6.41M0.37339,667+35.11%+$1.67M0.02
Citigroup$5.97M0.35316,127+148.47%+$3.57M<0.01
Susquehanna International Group$5.95M0.35315,051+169.79%+$3.74M0.01
Granahan Investment Management$5.6M0.33296,570+28.51%+$1.24M0.2
Two Sigma$4.97M0.29263,277+132.84%+$2.84M0.01
Parkman Healthcare Partners Llc$4.91M0.29259,920+4.95%+$231,393.300.61
Nordea Investment Management Ab$4.89M0.29259,372+26.26%+$1.02M0.01
Goldman Sachs$4.73M0.28250,313-57.74%-$6.46M<0.01
Eventide Asset Management$4.53M0.26240,0000%+$00.07
Renaissance Technologies$4.54M0.26240,500+94.74%+$2.21M0.01
AXA$4.38M0.26232,072+0.03%+$1,189.440.01
DAFNA Capital Management, LLC$4.37M0.26231,717-0.43%-$18,880.000.11
UBS$3.94M0.23208,729+28.46%+$873,105.71<0.01
PLATINUM INVESTMENT MANAGEMENT LTD$3.86M0.23204,3980%+$00.05
Invesco$3.6M0.21190,683-1.01%-$36,759.36<0.01
Barclays$3.55M0.21187,871-7.4%-$283,694.96<0.01
Gilder Gagnon Howe & Co. LLC$3.3M0.19174,655+25.5%+$669,957.530.04
RhumbLine Advisers$3.26M0.19172,673+0.78%+$25,204.60<0.01
Hudson Bay Capital Management LP$3.12M0.18165,000-2.94%-$94,400.000.02
Legal & General$2.84M0.17150,252+0.89%+$24,959.37<0.01
Bank of America$2.82M0.16149,552-9.3%-$289,619.33<0.0001
Nuveen$2.4M0.14127,219-4.67%-$117,584.65<0.01
Public Sector Pension Investment Board$2.11M0.12111,8460%+$00.02
Schonfeld Group$1.96M0.11103,860-55%-$2.4M0.01
New York State Teachers Retirement System$1.88M0.1199,7510%+$0<0.01
Allianz Asset Management Gmbh$1.86M0.1198,300+321.89%+$1.42M<0.01
PDT Partners$1.83M0.1197,152+548.8%+$1.55M0.14
Swiss National Bank$1.8M0.1195,3960%+$0<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.